In the booming age of digital health, there is no shortage of effective, low cost, and convenient ways to capture on-demand health data anytime, anywhere. Although, historically, some may see digital health tools as “gadgets”, their relevance and utilization in healthcare settings is expanding. Digital health is transforming the way healthcare professionals care for their patients, opening the doors to personalized treatment plans that may improve outcomes.
Because certain medications may have potential adverse effects on patients, many healthcare professionals reconsider prescribing them, despite some of these medications having a higher efficacy than their alternatives. What if there was a way to assess the potential risks of a more efficacious medication quickly and easily prior to its prescription? Enter digital health tools.
In this webinar, speakers from AliveCor and Market Dynamics will discuss how digital health tools are currently being used to enhance personalized medicine through cardiac safety monitoring programs. This duo will showcase a real-world example where oncologists use KardiaMobile 6L—a handheld and Bluetooth-enabled, FDA-cleared ECG device—prior to prescribing a cancer medication that may lead to adverse cardiac events such as QT prolongation.
Register for this webinar to learn how the adoption of digital health tools can improve patient outcomes by providing accurate, personalized, medical-grade data when it matters most.
David Market, Principal Managing Director, Market Dynamics, LLC
David Market has over 30 years of experience developing market access plans and streamlining patient services in both pharma and biotech. Founder of Market Dynamics, a market access strategy consulting firm, David specializes in creating clinical service programs that support patients in receiving digital therapeutics to enhance patient outcomes. Market Dynamics is proud to enable physicians, oncologists, gastroenterologists, neurologists and other medical specialties with new-aged digital health tools to efficiently evaluate patients’ health and make informed decisions when it comes to individualizing patient treatment plans.Message Presenter
Aman H. Bhatti, MD, Vice President of Global Medical Affairs & Head of BioPharma Partnerships at AliveCor Inc.
Dr. Aman Bhatti is currently the Global Head of AliveCor BioPharma, the group at AliveCor specializing in strategic partnerships with CROs and biopharmaceutical companies to enable decentralized clinical trials, create drugs+/beyond-the-pill solutions, develop new cardiac algorithms, and to enable convenient cardiac safety monitoring both in-office and in the patient’s home. Dr. Bhatti is a physician, digital health futurist and pharmaceutical executive focused on developing revolutionary technologies to increase healthcare accessibility, predict disease onset, prevent disease progression, and improve health outcomes worldwide. He is a firm believer in a holistic digital healthcare practice that offers patients products and services that go beyond just treating their disease and symptoms.
Prior to joining AliveCor, Dr. Bhatti had over a decade of experience as a global medical & innovation leader for major household healthcare brands including Mucinex, Theraflu, Flonase, Nicorette, Allegra, and Nasacort at leading pharmaceutical companies including Reckitt Benckiser, Novartis, GSK, and Sanofi.Message Presenter
Who Should Attend?
- Clinical Operations
- Clinical Trial Organizer
- Clinical Research Organization
- Head of Clinical Research
- Clinical Development
- Health Program Managers
- Pharmaceutical Companies
- Academic Research Organization
What You Will Learn
In this webinar, attendees will learn about:
- Implementing digital health tools to personalize patient care
- The use of digital tools in cardiac safety monitoring programs
- Innovative digital health collaborations that are improving patient outcomes
AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile device is the most clinically validated personal ECG solution in the world. KardiaMobile 6L provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular Contractions, Sinus Rhythm with Wide QRS and Normal Heart Rhythm in an ECG. Kardia is the first AI-enabled platform to aid patients and clinicians in the early detection of atrial fibrillation, the most common arrhythmia and one associated with a highly-elevated risk of stroke. AliveCor’s enterprise platform allows third party providers to manage their patients’ and customers’ heart conditions simply and profitably using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies. AliveCor protects its customers with stringent data security and compliance practices, achieving HIPAA compliance and SOC2 Type 1 and Type 2 attestations. For more information, visit alivecor.com.